Can B Corp is a small health and wellness company operating across hemp-derived CBD products, durable medical equipment (DME), and cannabis IP licensing. The company's legacy operations include manufacturing and selling CBD products — tinctures, topicals, and capsules — under the Canbiola and Pure Leaf Oil brands, sold directly to consumers and through medical professionals. Through its Duramed subsidiary, Can B Corp also distributes a therapeutic ultrasound device and back support braces to post-surgery patients through the no-fault insurance channel in New York and Michigan. Both legacy businesses are currently running at reduced capacity following an asset auction in early 2024 that stripped much of the hemp division's equipment and constrained Duramed's operations. Going forward, Can B Corp's primary focus is commercializing cannabis patents held through its 67% owned subsidiary, Nascent Pharma. These patents cover liquid cannabis formulations — including beverages, tinctures, vape liquids, and liquid-filled capsules — where cannabinoid purity exceeds 95%. Can B Corp intends to license these patents to third parties rather than manufacture products itself. The patents have been granted in several international markets and expire in August 2034, though Can B Corp has not yet disclosed any licensing agreements, and the company employs only 12 full-time employees.